Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Beta Bionics, Inc. before investing.

In this article, we go over a few key elements for understanding Beta Bionics, Inc.’s stock price such as:

• Beta Bionics, Inc.’s current stock price and volume
• Why Beta Bionics, Inc.’s stock price changed recently
• Upgrades and downgrades for BBNX from analysts
• BBNX’s stock price momentum as measured by its relative strength

About Beta Bionics, Inc. (BBNX)

Before we jump into Beta Bionics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.

Want to learn more about Beta Bionics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Beta Bionics, Inc..

Beta Bionics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Beta Bionics, Inc.’s stock price was $12.830.

Beta Bionics, Inc. is down 10.09% from its previous closing price of $14.270.

During the last market session, Beta Bionics, Inc.’s stock traded between $12.790 and $14.280. Currently, there are approximately 44.55 million shares outstanding for Beta Bionics, Inc..

Beta Bionics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Beta Bionics, Inc. Stock Price History

Beta Bionics, Inc.’s (BBNX) price is currently down 18.12% so far this month.

During the month of July, Beta Bionics, Inc.’s stock price has reached a high of $18.200 and a low of $12.790.

Over the last year, Beta Bionics, Inc. has hit prices as high as $32.710 and as low as $8.800. Year to date, Beta Bionics, Inc.’s stock is down 57.89%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Beta Bionics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Beta Bionics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Beta Bionics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Beta Bionics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Beta Bionics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Beta Bionics, Inc. (BBNX) by visiting AAII Stock Evaluator.

Relative Price Strength of Beta Bionics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Beta Bionics, Inc. has a weighted four-quarter relative price strength of 2.00%, which translates to a Momentum Score of 60 and is considered to be Average.

Want to learn more about how Beta Bionics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Beta Bionics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Beta Bionics, Inc.’s stock price is $12.830, which is down 10.09% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Beta Bionics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.